Antizyme Inhibitor 1: a Potential Carcinogenic Molecule

Overview

Journal Cancer Sci

Specialty Oncology

Date 2016 Nov 22

PMID 27870265

Citations 19

Authors

Shiqiao Qiu

Jing Liu

Feiyue Xing

Affiliations

Soon will be listed here.

Abstract

Polyamines are multivalent and organic cations essential for cellular growth, proliferation, differentiation, and apoptosis. Increased levels of polyamines are closely associated with numerous forms of cancer. An autoregulatory circuit composed of ornithine decarboxylase (ODC), antizyme (AZ) and antizyme inhibitor (AZI) govern the intracellular level of polyamines. Antizyme binds with ODC to inhibit ODC activity and to promote the ubiquitin-independent degradation of ODC. Antizyme inhibitor binds to AZ with a higher affinity than ODC. Consequently, ODC is released from the ODC-AZ complex to rescue its activity. Antizyme inhibitor increases the ODC activity to accelerate the formation of intracellular polyamines, triggering gastric and breast carcinogenesis as well as hepatocellular carcinoma and esophageal squamous cell carcinoma development. Antizyme inhibitor 1 (AZIN1), a primary member of the AZI family, has aroused more attention because of its contribution to cancer. Even though its conformation is changed by adenosine-to-inosine (A→I) RNA editing, it plays an important role in tumorigenesis through regulating intracellular polyamines. Encouragingly, AZIN1 has been revealed to have an additional function outside the polyamine pathway so as to bypass the deficiency of targeting the polyamine biosynthetic pathway, promising to become a critical target for cancer therapy. Here, we review the latest research advances into AZIN1 and its potential contribution to carcinogenesis.

Citing Articles

AZIN1 level is increased in medulloblastoma and correlates with c-Myc activity and tumor phenotype.

Sesen J, Martinez T, Busatto S, Poluben L, Nassour H, Stone C J Exp Clin Cancer Res. 2025; 44(1):56.

PMID: 39962590 PMC: 11831846. DOI: 10.1186/s13046-025-03274-1.

Nc-RNA-mediated low expression of AZIN1 correlated with unfavorable prognosis in kidney renal clear cell carcinoma.

Zeng X, Du S, Geng L, Ma J Cancer Med. 2024; 13(15):e70105.

PMID: 39140420 PMC: 11322861. DOI: 10.1002/cam4.70105.

Unveiling the hidden players: noncoding RNAs orchestrating polyamine metabolism in disease.

Rossi M, Fiorucci C, Mariottini P, Cervelli M Cell Biosci. 2024; 14(1):84.

PMID: 38918813 PMC: 11202255. DOI: 10.1186/s13578-024-01235-3.

Antizyme inhibitor family: biological and translational research implications.

Feng Q, Wang H, Shao Y, Xu X Cell Commun Signal. 2024; 22(1):11.

PMID: 38169396 PMC: 10762828. DOI: 10.1186/s12964-023-01445-1.

EPLIN-β is a novel substrate of ornithine decarboxylase antizyme 1 and mediates cellular migration.

Li D, Neo S, Gunaratne J, Sabapathy K J Cell Sci. 2023; 136(12).

PMID: 37325974 PMC: 10281260. DOI: 10.1242/jcs.260427.

References

Keren-Paz A, Bercovich Z, Porat Z, Erez O, Brener O, Kahana C . Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions. Oncogene. 2006; 25(37):5163-72. DOI: 10.1038/sj.onc.1209521. View

Bercovich Z, Kahana C . Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J Biol Chem. 2004; 279(52):54097-102. DOI: 10.1074/jbc.M410234200. View

Lopez-Contreras A, Ramos-Molina B, Cremades A, Penafiel R . Antizyme inhibitor 2: molecular, cellular and physiological aspects. Amino Acids. 2009; 38(2):603-11. DOI: 10.1007/s00726-009-0419-4. View

Li R, Chung A, Dong Y, Yang W, Zhong X, Lan H . The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-β/Smad3-Azin1 pathway. Kidney Int. 2013; 84(6):1129-44. DOI: 10.1038/ki.2013.272. View

Kasbek C, Yang C, Yusof A, Chapman H, Winey M, Fisk H . Preventing the degradation of mps1 at centrosomes is sufficient to cause centrosome reduplication in human cells. Mol Biol Cell. 2007; 18(11):4457-69. PMC: 2043537. DOI: 10.1091/mbc.e07-03-0283. View

Finn R, Aleshin A, Slamon D . Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016; 18(1):17. PMC: 4746893. DOI: 10.1186/s13058-015-0661-5. View

Schaner M, Ross D, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M . Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003; 14(11):4376-86. PMC: 266758. DOI: 10.1091/mbc.e03-05-0279. View

Peng L, Guo J, Zhang Z, Shi H, Wang J, Friedman S . [Polymorphism of ornithine decarboxylase antizyme inhibitor 1 gene is associated with liver cirrhosis in Chinese hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(3):169-73. DOI: 10.3760/cma.j.issn.1007-3418.2011.03.005. View

Belloni L, Moretti F, Merlo P, Damalas A, Costanzo A, Blandino G . DNp73alpha protects myogenic cells from apoptosis. Oncogene. 2006; 25(25):3606-12. DOI: 10.1038/sj.onc.1209321. View

10.

Mitchell J, Thane T, Sequeira J, Marton L, Thokala R . Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids. 2007; 33(2):291-7. DOI: 10.1007/s00726-007-0523-2. View

11.

Lim S, Gopalan G . Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene. 2007; 26(46):6593-603. DOI: 10.1038/sj.onc.1210482. View

12.

Gerner E, Meyskens Jr F . Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004; 4(10):781-92. DOI: 10.1038/nrc1454. View

13.

Lee C, Liu Y, Lin C, Liu G, Hung H . Functional roles of the dimer-interface residues in human ornithine decarboxylase. PLoS One. 2014; 9(8):e104865. PMC: 4139326. DOI: 10.1371/journal.pone.0104865. View

14.

Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C . Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci. 2008; 17(5):793-802. PMC: 2327289. DOI: 10.1110/ps.073427208. View

15.

Newman R, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M . Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem. 2004; 279(40):41504-11. DOI: 10.1074/jbc.M407349200. View

16.

Choi K, Suh Y, Kim W, Lee T, Jung M . Stable siRNA-mediated silencing of antizyme inhibitor: regulation of ornithine decarboxylase activity. Biochem Biophys Res Commun. 2005; 328(1):206-12. DOI: 10.1016/j.bbrc.2004.11.172. View

17.

Crews L, Jiang Q, Zipeto M, Lazzari E, Court A, Ali S . An RNA editing fingerprint of cancer stem cell reprogramming. J Transl Med. 2015; 13:52. PMC: 4341880. DOI: 10.1186/s12967-014-0370-3. View

18.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

19.

Ramos-Molina B, Lopez-Contreras A, Cremades A, Penafiel R . Differential expression of ornithine decarboxylase antizyme inhibitors and antizymes in rodent tissues and human cell lines. Amino Acids. 2011; 42(2-3):539-47. DOI: 10.1007/s00726-011-1031-y. View

20.

Liu Y, Lee C, Lin C, Chen H, Liu G, Hung H . Multifaceted interactions and regulation between antizyme and its interacting proteins cyclin D1, ornithine decarboxylase and antizyme inhibitor. Oncotarget. 2015; 6(27):23917-29. PMC: 4695161. DOI: 10.18632/oncotarget.4469. View